Biogen (BIIB.US) Q3 results exceed expectations, rare disease drug sales remain strong
智通财经2026/10/28 11:13Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
智通财经APP has learned that Biogen (BIIB.US) released its third-quarter results before market open on October 28: total revenue reached $2.804 billion, representing an 11% year-on-year increase and 10% growth at constant currency, surpassing market expectations of $2.63 billion to $2.68 billion; adjusted diluted earnings per share were $2.62, higher than the expected approximately $1.99, but down 46% year-on-year. Strong demand for the company’s rare disease and Alzheimer’s drugs helped offset the decline in sales of multiple sclerosis treatments.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Baidu Q3 2026 revenue reaches 30.807 billions RMB, down year-on-year
智通财经•2026/11/16 09:21
Spot platinum broke through the $1460/oz mark and then fell back to $1459.70/oz.
智通财经•2026/11/16 09:16

Crypto prices
MoreBitcoin
BTC
$64,241.27
-2.10%
Ethereum
ETH
$1,797.28
-1.83%
Tether USDt
USDT
$0.9990
-0.05%
BNB
BNB
$587.58
-1.86%
USDC
USDC
$0.9998
-0.01%
XRP
XRP
$0.9437
-2.76%
Solana
SOL
$70.71
-2.01%
TRON
TRX
$0.3023
-1.69%
Hyperliquid
HYPE
$66.55
-0.84%
Zcash
ZEC
$885.66
-2.67%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now